Imprimis Pharma makes US$1dollar alternative to US$750 dollar drug
Imprimis Pharmaceuticals made a low-cost alternative to Daraprim. Imprimis’s formulation costs less than a dollar a pop, compared to Daraprim which costs US$750 per tablet.
Last month, Turing Pharmaceuticals LLC, the sole supplier of Daraprim, increased the price of this prescription drug from US$13.50 per tablet to a reported US$750.00 per tablet.
The FDA-approved label for Daraprim indicates that it is prescribed for toxoplasmosis and other types of infections. Toxoplasmosis can be of major concern for patients with weakened immune systems such as patients with HIV/AIDS, pregnant women and children.
According to the Centers for Disease Control and Prevention, pyrimethamine works to block folic acid synthesis in the parasite T. gondii, the cause of toxoplasmosis, and leucovorin helps to reverse the negative effects on bone marrow caused by this mechanism of action.
Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as US$99.00 for a 100 count bottle, or at a cost of under a dollar per capsule. Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient.
Mark L. Baum, CEO of Imprimis said his company will be Imprimis Cares which is aligned to our corporate mission of making novel and customizable medicines available to physicians and patients today at accessible prices.
Category: Features, Pharmaceuticals
